STRS Ohio’s Keros Therapeutics KROS Stock Holding History

STRS Ohio’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,600	Closed	-$559K	–	2249
2026 Q1	$559K	Buy	50,600 +21,300	+73%	+$329K	﹤0.01%	1020
2025 Q4	$597K	Buy	29,300 +1,100	+4%	+$19.3K	﹤0.01%	939
2025 Q3	$446K	Buy	28,200 +18,800	+200%	+$278K	﹤0.01%	1156
2025 Q2	$125K	Buy	+9,400	New	+$127K	﹤0.01%	1799
2023 Q3	–	Sell	-5,700	Closed	-$229K	–	2003
2023 Q2	$229K	Buy	5,700 +400	+8%	+$17.5K	﹤0.01%	1562
2023 Q1	$226K	Hold	5,300	–	–	﹤0.01%	1575
2022 Q4	$254K	Hold	5,300	–	–	﹤0.01%	1533
2022 Q3	$199K	Buy	+5,300	New	+$184K	﹤0.01%	1606
2021 Q3	–	Sell	-2,000	Closed	-$84K	–	2283
2021 Q2	$84K	Buy	2,000 +200	+11%	+$10.8K	﹤0.01%	2012
2021 Q1	$110K	Hold	1,800	–	–	﹤0.01%	1924
2020 Q4	$126K	Hold	1,800	–	–	﹤0.01%	1845
2020 Q3	$69K	Hold	1,800	–	–	﹤0.01%	1913
2020 Q2	$67K	Buy	+1,800	New	+$55.5K	﹤0.01%	1861

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

STRS Ohio's KROS Position: Q2 2026 in Review

STRS Ohio sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 50,600 shares — an estimated $559K sold.

STRS Ohio first reported a position in KROS in Q2 2020 and held it in 13 quarters. The position peaked at $597K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

STRS Ohio reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
STRS Ohio sold 50,600 Keros Therapeutics shares in Q2 2026, an estimated $559K.
STRS Ohio first reported a position in Keros Therapeutics in Q2 2020 and held it in 13 quarters.
STRS Ohio's Keros Therapeutics position peaked at $597K in Q4 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.